ACADIA Pharmaceuticals (MEX:ACAD) Retained Earnings: MXN-32,635 Mil (As of Mar. 2026)


MEX:ACAD ACADIA Pharmaceuticals Inc MEX:ACAD
74 GF Score
Price MXN460.00
GF Value MXN442.46
Valuation Fairly Valued
! 10 Warning Signs
View Full Analysis

What is ACADIA Pharmaceuticals Retained Earnings?

ACADIA Pharmaceuticals MEX:ACAD 74 Retained Earnings is MXN-32,635 Mil as of Mar. 2026. GuruFocus rates MEX:ACAD with a GF Score™ of 74/100 and a GF Value™ of MXN442.46 (Fairly Valued). The stock has 10 warning signs investors should review.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. ACADIA Pharmaceuticals's retained earnings for the quarter that ended in Mar. 2026 was MXN-32,635 Mil.

ACADIA Pharmaceuticals's quarterly retained earnings increased from Sep. 2025 (MXN-38,284 Mil) to Dec. 2025 (MXN-32,651 Mil) and increased from Dec. 2025 (MXN-32,651 Mil) to Mar. 2026 (MXN-32,635 Mil).

ACADIA Pharmaceuticals's annual retained earnings declined from Dec. 2023 (MXN-41,262 Mil) to Dec. 2024 (MXN-45,974 Mil) but then increased from Dec. 2024 (MXN-45,974 Mil) to Dec. 2025 (MXN-32,651 Mil).


ACADIA Pharmaceuticals  (MEX:ACAD) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


ACADIA Pharmaceuticals Retained Earnings Historical Data

* Premium members only.

The historical data trend for ACADIA Pharmaceuticals's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ACADIA Pharmaceuticals Retained Earnings Chart

ACADIA Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only -44,178.46 -46,196.77 -41,261.63 -45,974.01 -32,651.28

ACADIA Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -44,709.33 -40,647.22 -38,283.50 -32,651.28 -32,634.66
MEX:ACAD
74GF Score
ACADIA Pharmaceuticals Inc MEX:ACAD
Retained Earnings is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ACADIA Pharmaceuticals Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of MXN-32,635 Mil mean?
ACADIA Pharmaceuticals (MEX:ACAD) has a Retained Earnings of MXN-32,635 Mil as of Mar. 2026. Retained earnings is the amount of net income not issued to shareholders. View historical data on ACADIA Pharmaceuticals and its competitors.
Is ACADIA Pharmaceuticals' Retained Earnings too high?
ACADIA Pharmaceuticals' current Retained Earnings is MXN-32,635 Mil. Overall, ACADIA Pharmaceuticals has a GF Score™ of 74/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does ACADIA Pharmaceuticals' Retained Earnings compare to VKTX and EWTX?
ACADIA Pharmaceuticals' Retained Earnings of MXN-32,635 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Biotechnology company?
A good Retained Earnings depends on the Biotechnology industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on ACADIA Pharmaceuticals and its competitors. ACADIA Pharmaceuticals's current Retained Earnings is MXN-32,635 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ACADIA Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, ACADIA Pharmaceuticals (MEX:ACAD) is currently considered Fairly Valued. The stock's GF Value™ is MXN442.46, compared to a current price of MXN460.00 — trading 4% above its estimated fair value. The current Retained Earnings is MXN-32,635 Mil. ACADIA Pharmaceuticals' overall GF Score™ is 74/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For ACADIA Pharmaceuticals (MEX:ACAD), the current Retained Earnings is MXN-32,635 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ACADIA Pharmaceuticals (MEX:ACAD) Overvalued in 2026?

Based on GuruFocus' analysis, ACADIA Pharmaceuticals stock appears to be overvalued. The current stock price of MXN460.00 is trading 4% above its estimated GF Value™ of MXN442.46. GuruFocus considers ACADIA Pharmaceuticals to be Fairly Valued.

Key valuation signals for MEX:ACAD:

  • Retained Earnings: MXN-32,635 Mil
  • GF Value™: MXN442.46 vs. price of MXN460.00 (4% above fair value)
  • GF Score™: 74/100 with 10 warning signs

No single metric tells the full story. See the MEX:ACAD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


ACADIA Pharmaceuticals Business Description

Other Exchanges ACAD:USADR6:Germany
Address 12830 El Camino Real, Suite 400, San Diego, CA, USA, 92130
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-211, ACP-711, ACP-2591, etc.
74GF Score

Get the complete analysis for MEX:ACAD

Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN460.00
Price
MXN442.46
GF Value